The Optimal Sequential Therapy After Long Term Denosumab Treatment

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study intends to investigate whether Alendronate and Zoledronate can prevent bone mineral density loss after long-term treatment with Denosumab.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Treatments: Alendronate; Zoledronic Acid

Criteria

Inclusion Criteria:

1. Postmenopausal women or men over 50 years old

2. Denosumab treatment for at least two years and less than three years (up to five doses).

Exclusion Criteria:

1. Estimated glomerular filtration rate <35 ml/min.

2. Malignancy

3. Continuous steroid treatment, hormone therapy or other medical treatment affecting bone metabolism

4. Secondary osteoporosis

5. Metabolic bone diseases

6. Contraindications to ZOL

7. Patients older than 80 years old

8. Hypocalcemia